Tocqueville Asset Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Tocqueville Asset Management’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13	Closed	-$57.4K	–	551
2023 Q2	$57.4K	Sell	13 -2	-13%	-$6.94K	﹤0.01%	527
2023 Q1	$40.1K	Buy	15 +1	+7%	+$2.93K	﹤0.01%	524
2022 Q4	$37.3K	Hold	14	–	–	﹤0.01%	571
2022 Q3	$57K	Sell	14 -17	-55%	-$66.9K	﹤0.01%	589
2022 Q2	$81K	Hold	31	–	–	﹤0.01%	651
2022 Q1	$99K	Hold	31	–	–	﹤0.01%	695
2021 Q4	$193K	Sell	31 -1	-3%	-$7.68K	﹤0.01%	717
2021 Q3	$299K	Sell	32 -9	-22%	-$77.3K	﹤0.01%	625
2021 Q2	$419K	Sell	41 -11	-21%	-$181K	0.01%	590
2021 Q1	$992K	Buy	52 +25	+93%	+$292K	0.02%	450
2020 Q4	$166K	Buy	27 +17	+170%	+$66.7K	﹤0.01%	688
2020 Q3	$37K	Sell	10 -37	-79%	-$133K	﹤0.01%	643
2020 Q2	$183K	Sell	47 -3	-6%	-$9.96K	﹤0.01%	631
2020 Q1	$94K	Buy	+50	New	+$186K	﹤0.01%	621

Other funds holding SEEL

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Tocqueville Asset Management's SEEL Position: Q3 2023 in Review

Tocqueville Asset Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2023, closing a stake of 13 shares — an estimated $57.4K sold.

Tocqueville Asset Management first reported a position in SEEL in Q1 2020 and held it in 14 quarters. The position peaked at $992K in Q1 2021. 67 funds tracked by Wall St. Rank hold SEEL as of Q3 2023.

Tocqueville Asset Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Tocqueville Asset Management sold 13 Seelos Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $57.4K.
Tocqueville Asset Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 14 quarters.
Tocqueville Asset Management's Seelos Therapeutics, Inc. Common Stock position peaked at $992K in Q1 2021.
67 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Tocqueville Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.